| HOME >> BIOLOGY >> TECHNOLOGY |
Issued and outstanding: nil
Common stock 42,854 40,305
Authorized: 100,000,000 shares at
par value of $0.001 each
Issued and outstanding: 42,853,528
(2007 - 40,305,028 )
Subscriptions received 39,295 9,170
Additional paid in capital 41,965,154 32,109,997
Accumulated other comprehensive income 4,199,660 1,956,456
Dedicated reserves 2,999,396 2,999,396
Accumulated deficit (2,215,264) (7,111,469)
Total stockholders' equity 47,031,095 30,003,855
Total liabilities and stockholders'
equity $ 79,089,467 $ 57,447,962
SINOVAC BIOTECH LTD.
Consolidated Statements of Cash Flows
Three Months and Six Months Ended June 30, 2008 and 2007
(Unaudited)
(Expressed in U.S. Dollars)
Three Months Ended June 30 Six Months Ended June 30
2008 2007 2008 2007
Cash flows from (used in)
operating activities
Net Income for the
period $3,336,249 $2,690,607 $4,896,205 $3,466,979
Adjustments to
reconcile net income to
net cash used by
operating activities:
- deferred income taxes (970,614) 66,336 (897,433) 118,071
- loss on disposal of
equipment -- 3,957 -- 3,957
- stock-based compensation 16,635 69,276 33,271 138,551
- provision for doubtful
debts 932,113 570,302 1,559,918 754,544
- inventory provision
'/>"/>
| SOURCE Sinovac Biotech Ltd. Copyright©2008 PR Newswire. All rights reserved |